openPR Logo
Press release

Global T Cell Lymphoma Market & Clinical Pipeline Insight Report

05-07-2018 08:49 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global T Cell Lymphoma Market & Clinical Pipeline Insight Report

“Global T-Cell Lymphoma Market & Clinical Pipeline Insight” Report Highlight:

* Mechanism of T-Cell Lymphoma Therapeutics
* T-Cell Lymphoma Drug Market Overview
* T-Cell Lymphoma Drug Clinical Pipeline By Company & Phase
* T-Cell Lymphoma Drug Clinical Pipeline By Peripheral & Cutaneous T-cell Lymphoma
* T-Cell Lymphoma Drug Clinical Pipeline: 24 Drugs
* Orphan Designated T-Cell Lymphoma Drugs: 22 Drugs
* Marketed T Cell Lymphoma Drug Clinical Insight
* Marketed T Cell Lymphoma Drugs: 15 Drugs
* T-Cell Lymphoma Drug Market Future Prospects

Download Report Sample Weblink:

https://www.kuickresearch.com/report-Global-T-Cell-Lymphoma-Market-&-Clinical-Pipeline-Insight.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. T-Cell Lymphoma Market Analysis



2. Mechanism of T-Cell Lymphoma Therapeutics



3. T-Cell Lymphoma Drug Market Overview

3.1 Current Market Scenario

3.2 T Cell Lymphoma Clinical Pipeline Overview



4. T-Cell Lymphoma Drug Market Dynamics

4.1 Favorable Market Parameters

4.2 Commercialization Challenges



5. T-Cell Lymphoma Drug Market Future Prospects



6. T-Cell Lymphoma Drug Clinical Pipeline By Company & Phase

6.1 Research

6.2 Preclinical

6.3 Clinical

6.4 Phase-I

6.5 Phase-I/II

6.6 Phase-II

6.7 Phase-II/III

6.8 Phase-III



7. Marketed T-Cell Lymphoma Drug Clinical Insight

7.1 Belinostat (Beleodaq)

7.2 Denileukin Diftitox (ONTAK)

7.3 Mogamulizumab (Poteligeo)

7.4 Brentuximab Vedotin (Adcetris)

7.5 Pralatrexate (Difolta/Folotyn)

7.6 Interferon gamma 1a Biosimilar (Imunomax-γ)

7.7 Nelarabine (Arranon/ Atriance)

7.8 Vorinostat (Zolinza)

7.9 Romidepsin (Istodax)

7.10 Bexarotene Topical (Targretin Gel)

7.11 Bexarotene Oral (Targretin Oral)

7.12 Chlormethine (Ledaga/Valchlor

7.13 Methoxsalen Solution (UVADEX)

7.14 Mogamulizumab Companion Diagnostics (Poteligeo Test FCM/IHC)

7.15 Interferon alpha-2a (Roferon-A)



8. Discontinued & No Development Reported in T-Cell Lymphoma Drug in Clinical Pipeline

8.1 Discontinued

8.2 No Development Reported



9. Competitive Landscape

9.1 Actelion Pharmaceuticals

9.2 Allos Therapeutics

9.3 Astellas Pharma

9.4 BioCryst Pharmaceuticals

9.5 Bristol-Myers Squibb

9.6 Chipscreen Biosciences

9.7 Celgene Corporation

9.8 Eisai

9.9 Genmab

9.10 Galderma

9.11 Inovio Pharmaceuticals

9.12 Johnson & Johnson Pharmaceutical Research & Development

9.13 Karyopharm Therapeutics

9.14 Kyowa Hakko Kirin

9.15 Nippon Kayaku

9.16 Novartis

9.17 Neumedicines

9.18 Onyx Pharmaceuticals

9.19 Roche

9.20 Seattle Genetics

9.21 Shionogi

9.22 Soligenix

9.23 TetraLogic Pharmaceuticals

9.24 ZIOPHARM Oncology

Figure 1-1: Main Types of Blood Cancer

Figure 1-2: Types of White Blood Cells (WBC)

Figure 1-3: Types of Lymphoma

Figure 1-4: Major Type of T-Cell Lymphoma

Figure 1-5: Type of Anaplastic Large Cell Lymphoma

Figure 1-6: Type of Uncommon T-Cell Lymphomas

Figure 2-1: Extracorporeal Photopheresis (ECPP)

Figure 2-2: Mechanism of Bexarotene

Figure 2-3: Mechanism of Pralatrexate

Figure 2-4: Mechanism of Vorinostat

Figure 2-5: Mechanism of Denileukin Diftitox

Figure 2-6: Mechanism of Romidepsin

Figure 2-7: Mechanism of Alemtuzumab

Figure 3-1: T-Cell Lymphoma Pipeline by Phase(%), 2016

Figure 3-2: T-Cell Lymphoma Pipeline by Phase(Numbers), 2016

Figure 3-3: T-Cell Lymphoma Pipeline by Phase (%), 2016

Figure 3-4: T-Cell Lymphoma Pipeline by Phase (Numbers), 2016

Figure 4-1: T-Cell Lymphoma Drug Market Favorable Parameters

Figure 4-1: T-Cell Lymphoma Drug Market Commercialization Challenges



Table 1-1: Staging of T-Cell Lymphoma

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global T Cell Lymphoma Market & Clinical Pipeline Insight Report here

News-ID: 1040954 • Views: 286

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases


More Releases for Lymphoma

Lymphoma Drugs Market Growth 2019-2024
According to 24 Market Reports study, over the next five years the Lymphoma Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. Lymphoma is cancer that begins in infection-fighting cells of the immune system, called lymphocytes. These cells are in the lymph nodes, spleen, thymus, bone marrow, and other parts of the
Lymphoblastic Lymphoma Market : Overview and Analysis
Lymphoblastic lymphoma involves both T-lymphocytes and B-lymphocytes, of which 84% to 90% cases of lymphoblastic lymphoma involve T-lymphocytes. Chemotherapy is the preferred choice and first line treatment in cases of lymphoblastic lymphoma, where the regimen is followed for the treatment and includes induction chemotherapy, consolidation chemotherapy, and continuing chemotherapy. Other treatments include radiotherapy which might be given in the brain or spine if lymphoma cells are present or in other
Burkitt Lymphoma Therapeutics Market Key Growth Drivers
Burkitt lymphoma is a form of non-Hodgkin's lymphomas (NHLs) which are a group of blood cancers derived from lymphocytes. Burkitt lymphoma is a rare disease and occurs only in one in every 30-50 people with non-Hodgkin's lymphomas. According to the World Health Organization (WHO), Burkitt lymphomas are of three types, namely, endemic, sporadic and immunodeficiency associated. Endemic NHL is also known as African type and affects African children aged between
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape. Hodgkin disease is a cancer of the lymphatic system. It
Lymphoma Therapeutics Market Report : 2017
Reports And Markets Publish a New Market Research Report On –"Lymphoma Therapeutics Market Report 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/united-states-lymphoma-therapeutics-market-report-2017-1541149 In this report, the United States Lymphoma Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. T-Cell Lymphoma Market Analysis 2. Mechanism of T-Cell Lymphoma Therapeutics 3. T-Cell Lymphoma Drug Market Overview 3.1 Current Market Scenario 3.2 T Cell Lymphoma Clinical Pipeline Overview 4. T-Cell Lymphoma Drug Market Dynamics 4.1 Favorable Market Parameters 4.2 Commercialization Challenges 5. T-Cell Lymphoma Drug Market Future Prospects 6. T-Cell Lymphoma Drug Clinical Pipeline By Company